PANREAC presents a new line of excipients for the pharmaceutical industry according to the IPEC guide
For seven decades PANREAC has succeed in satisfying the needs of their costumers thanks to their extensive experience, their constant product innovation and quality research.
PANREAC, since its founding in 1941 is one of the Spanish leading companies specialized in the manufacturing of reagents for laboratory analysis, excipients and bulk chemicals to be used as raw materials in the pharmaceutical, cosmetic and food industries.
PANREAC has become a benchmark company in the pharmaceutical manufacturing process for their high quality standards established from the start. Since the company’s beginnings, they offered high purity products PRS for Pharmaceutical applications, becoming later the “PRS-CODEX’, an important level of commitment with the main pharmacopeias. Over last year they have launched a new line of excipients for the pharmaceutical industry fulfilling the guidelines of IPEC.
At the moment, Panreac Pharma counts with more than 300 raw materials for the pharmaceutical and biotechnology industry to be used as excipients or during the manufacturing process.
High Standards of Quality
The excipients are the main ingredient of the medicines in terms of volume and weight; therefore, they have an important function on the final product. For this reason, PANREAC has adopted the IPEC-PQG GMP guide for pharmaceutical excipients (2006), to ensure product consistent conformity through and integral control policy which Panreac has integrated into its manufacturing processes.
The line has an incredible detailed process description including registration, validation and release procedures and also supports supplier audits, upstream and downstream traceability and has a production sample storage. Furthermore, PANREAC has trained specialized workforce to assure the best quality and safety for the pharmaceutical industry and its potential consumers, offering maximum purity, reliability and a firm commitment to society that is finally translated into success and progress. PANREAC has built an exclusive “Clean Room Panreac Pharma” aimed just to develop excipients within strict work conditions in terms of hygiene and contamination control.
PANREAC also disposes of the ISO 9001:2008 on quality management, ISO 14002:2004 on environmental protection and OHSAS 18001:2007 on the safety and health at work, three more commitments that justify one of their main company values: be at the leading edge of quality assurance in the sector.
Fast market development
For seven decades PANREAC has succeed in satisfying the needs of their costumers thanks to their extensive experience, their constant product innovation and quality research.
Thereby, in order to respond the constant increasing market demands, PANREAC disposes of a 15000 m2 high-tech production plant near Barcelona that allows them to optimize flexibility and efficiency in their production. Moreover, since 2008 they developed a new 8000 m2 technologically equipped warehouse to provide the best service to customers and distributors.
Particularly, the company has worked hard to truly expand their products and services internationally. So, for this reason, in 1999 they opened their first two subsidiaries in France and Portugal. Lately in 2007 PANREAC bought the Italian company Nova Chimica, allowing them to get faster in the European market. In 2010 Panreac became part of the chemical division (performance polymers and fluids group) of Illinois Tool Works (ITW), an $18 billion per year U.S. industrial conglomerate.
Nowadays, PANREAC exports their products to more than 80 countries in the world, thanks to their growing and expanding distribution network.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance